dacomitinib (egfr inhibitor) for lung cancer patients - what is it?
Published 10 years ago • 884 plays • Length 4:38Download video MP4
Download video MP3
Similar videos
-
1:36
dr. mark kris discusses dacomitinib for patient with egfr-positive lung cancer
-
1:21
dr. bertino on frontline dacomitinib in metastatic egfr nsclc
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
30:57
dacomitinib: new treatment paradigm in the management of egfr mutation positive nsclc
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
7:05
is dacomitinib survival benefit enough to make it a contender as first line treatment? (bmic-044)
-
6:03
promising egfr inhibitors in development for nsclc
-
5:52
treatment of egfr nsclc after osimertinib
-
8:23
dacomitinib in treatment-naïve egfr-mutated nsclc: real-world insights from india | crsf
-
7:59
dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc
-
4:25
do immune checkpoint inhibitors work in egfr mutant lung cancer?
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
0:52
dr. shum discusses dacomitinib in egfr nsclc
-
37:44
deciphering the data in egfr - mutant nsclc
-
8:44
adjuvant egfr inhibition in patients with nsclc
-
6:55
case 4: treating egfr nsclc after osimertinib
-
0:44
dr. mok on dacomitinib for first-line lung cancer treatment